CORBEVAX is anticipated to significantly expand vaccine access to people in low- and middle-income countries.
While neoliberalism has allowed U.S. markets to grow, the resultant stunted public health system left Americans to figure out how to protect themselves from COVID-19 and its fallout on their own.
Bat hosts, lab leaks – tracing SARS-CoV-2 to its origins involves more than just tracking down patient zero.
The US was not ready for the coronavirus pandemic in 2020. What can public health leaders and policymakers do to make sure we don't face another winter of rampant disease?
As ready as you are to be done with COVID-19, it's not going anywhere soon. A historian of disease describes how once a pathogen emerges, it's usually here to stay.
A new study is the first to identify sex differences in inflammation and immune cell activation in response to SARS-CoV-2 infection, which causes COVID-19.
During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.
Epidemiological data suggests that 80% of COVID-19 cases can be traced to just 20% of those infected with SARS-CoV-2.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
/
3
